Literature DB >> 17028184

L4-33K, an adenovirus-encoded alternative RNA splicing factor.

Heidi Törmänen1, Ellenor Backström, Anette Carlsson, Göran Akusjärvi.   

Abstract

Splicing of the adenovirus IIIa mRNA is subjected to a strict temporal regulation during virus infection such that efficient IIIa 3' splice site usage is confined to the late phase of the infectious cycle. Here we show that the adenovirus L4-33K protein functions as a virus-encoded RNA splicing factor that preferentially activates splicing of transcripts with a weak 3' splice site sequence context, a sequence configuration that is shared by many of the late adenovirus 3' splice sites. Furthermore, we show that L4-33K activates IIIa splicing through the IIIa virus infection-dependent splicing enhancer element (3VDE). This element was previously shown to be the minimal element, both necessary and sufficient, for activation of IIIa splicing in the context of an adenovirus-infected cell. L4-33K stimulates an early step in spliceosome assembly and appears to be the only viral protein necessary to convert a nuclear extract prepared from uninfected HeLa cells to an extract with splicing properties very similar to a nuclear extract prepared from adenovirus late-infected cells. Collectively, our results suggest that L4-33K is the key viral protein required to activate the early to late switch in adenovirus major late L1 alternative splicing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17028184     DOI: 10.1074/jbc.M607601200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Adenovirus late-phase infection is controlled by a novel L4 promoter.

Authors:  Susan J Morris; Gillian E Scott; Keith N Leppard
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

2.  Role for the L1-52/55K protein in the serotype specificity of adenovirus DNA packaging.

Authors:  Beverly P Wohl; Patrick Hearing
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

3.  Adenovirus serotype 5 L4-22K and L4-33K proteins have distinct functions in regulating late gene expression.

Authors:  Susan J Morris; Keith N Leppard
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

4.  The adenovirus L4-22K protein is multifunctional and is an integral component of crucial aspects of infection.

Authors:  Kai Wu; Diana Orozco; Patrick Hearing
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

5.  The adenovirus L4-33K protein regulates both late gene expression patterns and viral DNA packaging.

Authors:  Kai Wu; Diana Guimet; Patrick Hearing
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

6.  The adenovirus L4-22K protein has distinct functions in the posttranscriptional regulation of gene expression and encapsidation of the viral genome.

Authors:  Diana Guimet; Patrick Hearing
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

7.  Role of the RNA recognition motif of the E1B 55 kDa protein in the adenovirus type 5 infectious cycle.

Authors:  Sayuri E M Kato; Wenying Huang; S J Flint
Journal:  Virology       Date:  2011-05-24       Impact factor: 3.616

8.  Conserved arginines of bovine adenovirus-3 33K protein are important for transportin-3 mediated transport and virus replication.

Authors:  Vikas Kulshreshtha; Lisanework E Ayalew; Azharul Islam; Suresh K Tikoo
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

9.  Kaposi's sarcoma-associated herpesvirus ORF57 functions as a viral splicing factor and promotes expression of intron-containing viral lytic genes in spliceosome-mediated RNA splicing.

Authors:  Vladimir Majerciak; Koji Yamanegi; Eric Allemand; Michael Kruhlak; Adrian R Krainer; Zhi-Ming Zheng
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

10.  The influenza A virus spliced messenger RNA M mRNA3 is not required for viral replication in tissue culture.

Authors:  David Jackson; Robert A Lamb
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.